Xintela today announced that the company's international patent application directed to the prevention and treatment of degenerative joint diseases using stem cells, including osteoarthritis, has been published.
The data on which the patent application is based are derived from the horse study conducted by Xintela in late 2016. It demonstrated that stem cells, selected using Xintela’s marker technology, protect both joint cartilage and underlying bone following a cartilage injury.
The patent application extends patent protection for Xintela’s stem cell product for the treatment of traumatic joint damage, which may be caused by a sport injury, for example. The stem cell product aims to prevent degradation of joint cartilage and inhibit development of bone sclerosis, which are typical disease related changes in a joint afflicted with osteoarthritis. The application also covers the use of Xintela’s stem cell product for the treatment of degenerative joint diseases, including osteoarthritis and bone sclerosis.
"We are proactively working to broaden and strengthen our patent portfolio in both existing and new areas. In the horse study, we demonstrated that Xintela's selected stem cells have unique properties that make them suitable for both prevention and treatment of osteoarthritis and other degenerative joint diseases, "says Xintela’s CEO, Evy Lundgren-Åkerlund.
The horse study was conducted together with a research group at Cornell University, USA, and will be published in an international scientific journal. The results form an important part of the preclinical documentation for Xintela’s clinical studies in both humans and animals.
Xintela AB (publ)
Evy Lundgren-Åkerlund, CEO
Tel: 070-329 18 71
Email: evy [at] xintela.se
223 81 Lund